Moderna (MRNA) Raises 2026 Revenue Growth Outlook to 15-25%

Moderna (MRNA) reported third-quarter earnings per share of 38 cents, beating the expected loss of $1.25 per share. Its revenue rose 29% to $1.31 billion, surpassing the $885.1 million anticipated by analysts. The company posted net income of $162 million for the quarter, compared to a net loss of $200 million in the same period last year.

Moderna raised its 2026 revenue growth outlook to a range of 15% to 25%, up from a previous estimate of up to 10%. CEO Stéphane Bancel attributed the strong Q3 performance to new products and geographic diversification. The company highlighted the full-year effect of its next-generation mRNA Covid vaccine, approved in the U.S. in May 2025, and noted a limited launch in 2026 of its newly approved standalone flu shot.

Despite setbacks after partial data leaks related to its personalized cancer vaccine developed with Merck, Moderna emphasized positive feedback from long-term investors and medical professionals. The cancer vaccine data showed promise in advanced trials combined with immunotherapy Keytruda in melanoma patients. The firm’s progress on diversified vaccine offerings and expanding markets supports its updated revenue guidance.

This matters for investors as Moderna’s improved revenue forecast reflects strengthening sales momentum across key vaccine products, with its biopharma partnerships and new launches driving higher expected revenue growth in 2026.